Skip to content
DataLookout
Menu

NCT05052528

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

StatusSuspended
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial status changed: Active, Not Recruiting → Suspended Sponsor's reason: Pending IRB review.
  2. Notable Eligibility criteria expanded, about 11 words Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 5 entries
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 5 of 6 entries
    • Study description revised
    • Site details revised
  3. Notable Lead sponsor: Mehrdad Abedi, MD to University of California, Davisv4 Show 4 more changesShow less
    • Primary completion date: May 15, 2025 to May 15, 2027
    • Eligibility criteria expanded, about 109 words
    • Study completion date: Dec 15, 2025 to Dec 15, 2027
    • Site contact updated
  4. Notable Primary completion date: Aug 15, 2024 to May 15, 2025
    • Study completion date: Feb 15, 2025 to Dec 15, 2025
    v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 30, 2021 to Sep 17, 2021
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Proportion of products successfully manufactured meeting the established release criteria with a goal of at least 1.0 x 10^6 cells/kilogram
Timeframe: Up to 15 years
Incidence and severity of adverse events related to lymphodepleting chemotherapy and or CD19 chimeric antigen receptor (CAR) T cells
Timeframe: 2 months
Dose limiting toxicities (DLTs) related to lymphodepleting chemotherapy and or CD19 CAR T cells
Timeframe: 2 months
Maximum tolerated dose
Timeframe: 2 months
Incidence and severity of DLT associated with infusion of CD19 CAR T cells (infusion reactions)
Timeframe: 2 months

Secondary (6)

Incidence of toxicities related to CD19 CAR T cells
Overall response rate
Complete response rate
Overall survival
Progression free survival
Show 1 moreShow less
Event free survival

Arms and interventions

Dose level 1 (fludarabine, cyclophosphamide, CD19 CAR T)Experimental

Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.

Dose level 2 (rituximab, fludarabine, cyclophosphamide, CAR T)Experimental

Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.

Dose level 3 (fludarabine, cyclophosphamide, CD19 CAR T)Experimental

Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.

Dose level 4 (rituximab, fludarabine, cyclophosphamide, CAR T)Experimental

Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.

Dose level 5 (fludarabine, cyclophosphamide, CD19 CAR T)Experimental

Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.

Dose level 6 (rituximab, fludarabine, cyclophosphamide, CAR T)Experimental

Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.

Biologicals: Chimeric Antigen Receptor T-Cell Therapy, Rituximab

Drugs: Cyclophosphamide, Fludarabine Phosphate

Sites

1 site in 1 country

  • University of California Davis Comprehensive Cancer CenterSacramento, California, United States